565 related articles for article (PubMed ID: 18392810)
1. Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme.
Schaeffer EL; Gattaz WF
Psychopharmacology (Berl); 2008 May; 198(1):1-27. PubMed ID: 18392810
[TBL] [Abstract][Full Text] [Related]
2. Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease.
Schaeffer EL; Forlenza OV; Gattaz WF
Psychopharmacology (Berl); 2009 Jan; 202(1-3):37-51. PubMed ID: 18853146
[TBL] [Abstract][Full Text] [Related]
3. Differential roles of phospholipases A2 in neuronal death and neurogenesis: implications for Alzheimer disease.
Schaeffer EL; da Silva ER; Novaes Bde A; Skaf HD; Gattaz WF
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1381-9. PubMed ID: 20804810
[TBL] [Abstract][Full Text] [Related]
4. The cholinergic system in aging and neuronal degeneration.
Schliebs R; Arendt T
Behav Brain Res; 2011 Aug; 221(2):555-63. PubMed ID: 21145918
[TBL] [Abstract][Full Text] [Related]
5. Cholinergic systems and long-term potentiation in memory-impaired apolipoprotein E-deficient mice.
Krzywkowski P; Ghribi O; Gagné J; Chabot C; Kar S; Rochford J; Massicotte G; Poirier J
Neuroscience; 1999; 92(4):1273-86. PubMed ID: 10426483
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease amyloid beta-protein and synaptic function.
Ondrejcak T; Klyubin I; Hu NW; Barry AE; Cullen WK; Rowan MJ
Neuromolecular Med; 2010 Mar; 12(1):13-26. PubMed ID: 19757208
[TBL] [Abstract][Full Text] [Related]
7. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease.
Hynd MR; Scott HL; Dodd PR
Neurochem Int; 2004 Oct; 45(5):583-95. PubMed ID: 15234100
[TBL] [Abstract][Full Text] [Related]
8. Glutamatergic systems in Alzheimer's disease.
Francis PT
Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S15-21. PubMed ID: 12973746
[TBL] [Abstract][Full Text] [Related]
9. Animal models of Alzheimer's disease: glutamatergic denervation as an alternative approach to cholinergic denervation.
Myhrer T
Neurosci Biobehav Rev; 1993; 17(2):195-202. PubMed ID: 8515902
[TBL] [Abstract][Full Text] [Related]
10. NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer's disease.
Lin CH; Huang YJ; Lin CJ; Lane HY; Tsai GE
Curr Pharm Des; 2014; 20(32):5169-79. PubMed ID: 24410566
[TBL] [Abstract][Full Text] [Related]
11. Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer's Disease.
Cheng YJ; Lin CH; Lane HY
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668976
[TBL] [Abstract][Full Text] [Related]
12. Amyloid beta peptides and glutamatergic synaptic dysregulation.
Parameshwaran K; Dhanasekaran M; Suppiramaniam V
Exp Neurol; 2008 Mar; 210(1):7-13. PubMed ID: 18053990
[TBL] [Abstract][Full Text] [Related]
13. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
Wenk GL
J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
[TBL] [Abstract][Full Text] [Related]
14. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease.
Pákáski M; Kálmán J
Neurochem Int; 2008 Nov; 53(5):103-11. PubMed ID: 18602955
[TBL] [Abstract][Full Text] [Related]
15. Involvement of cytosolic phospholipase A(2), calcium independent phospholipase A(2) and plasmalogen selective phospholipase A(2) in neurodegenerative and neuropsychiatric conditions.
Ong WY; Farooqui T; Farooqui AA
Curr Med Chem; 2010; 17(25):2746-63. PubMed ID: 20586719
[TBL] [Abstract][Full Text] [Related]
16. The Dual Role of Glutamatergic Neurotransmission in Alzheimer's Disease: From Pathophysiology to Pharmacotherapy.
Bukke VN; Archana M; Villani R; Romano AD; Wawrzyniak A; Balawender K; Orkisz S; Beggiato S; Serviddio G; Cassano T
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050345
[TBL] [Abstract][Full Text] [Related]
17. Impaired muscarinic regulation of excitatory synaptic transmission in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
Goto Y; Niidome T; Hongo H; Akaike A; Kihara T; Sugimoto H
Eur J Pharmacol; 2008 Mar; 583(1):84-91. PubMed ID: 18282567
[TBL] [Abstract][Full Text] [Related]
18. Adverse psychological impact, glutamatergic dysfunction, and risk factors for Alzheimer's disease.
Myhrer T
Neurosci Biobehav Rev; 1998; 23(1):131-9. PubMed ID: 9861617
[TBL] [Abstract][Full Text] [Related]
19. NGF and the Amyloid Precursor Protein in Alzheimer's Disease: From Molecular Players to Neuronal Circuits.
Triaca V; Ruberti F; Canu N
Adv Exp Med Biol; 2021; 1331():145-165. PubMed ID: 34453297
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of phospholipase A₂ in rat brain modifies different membrane fluidity parameters in opposite ways.
Schaeffer EL; Skaf HD; Novaes Bde A; da Silva ER; Martins BA; Joaquim HD; Gattaz WF
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1612-7. PubMed ID: 21601609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
